Will targeting interleukin-6 in the anemia of CKD change our treatment paradigm?

Daniel W. Coyne; Robert Fleming

doi:10.1681/ASN.2020101476

Will targeting interleukin-6 in the anemia of CKD change our treatment paradigm?

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	6-8
Number of pages	3
Journal	Journal of the American Society of Nephrology
Volume	32
Issue number	1
DOIs	https://doi.org/10.1681/ASN.2020101476
State	Published - Jan 2021

Access to Document

10.1681/ASN.2020101476

Cite this

@article{09a18317c2bd4429a84acf833577b26e,

title = "Will targeting interleukin-6 in the anemia of CKD change our treatment paradigm?",

author = "Coyne, {Daniel W.} and Robert Fleming",

note = "Funding Information: D. Coyne is a consultant to Fresenius Medical Care-Renal Therapies Group, which sells intravenous iron, Rockwell Medical, a maker of triferic, an iron added to dialysate, and Vifor, a maker of intravenous iron. D. Coyne reports consultancy agreements with MC-RTG, Medibeacon, Reata, GSK, Fibrogen, and AstraZeneca; research funding from GSK; and honoraria from FMC-RTG, Medibeacon, GSK, Fibrogen, and AstraZeneca. R. Fleming conducts research and is a consultant to Rockwell Medical, maker of triferic, an iron added to dialysate. R. Fleming reports research funding from Ultragenyx Pharmaceuticals; reports being a scientific advisor or membership as a Scientific Advisory Board Member for Silence Therapeutics, and Protagonist Therapeutics.",

year = "2021",

month = jan,

doi = "10.1681/ASN.2020101476",

language = "English",

volume = "32",

pages = "6--8",

journal = "Journal of the American Society of Nephrology",